ImmunologybioRxivPreprint
A novel bacterial protease inhibitor adjuvant in RBD-based COVID-19 vaccine formulations increases neutralizing antibodies, specific germinal center B cells and confers protection against SARS-CoV-2 infection.
L. M. Coria, L. M. Saposnik, C. Pueblas Castro…·J. Cassataro
This paper evaluates RBD-based vaccine formulations with different adjuvants, finding that U-Omp19+Alum significantly increases neutralizing antibodies, B cells, and provides protection against SARS-CoV-2.
DOI 10.1101/2021.12.07.471590